Clinical trials: Prophylactic Anticoagulation
Heart Failure, Respiratory Insufficiency
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
The purpose of this study is to evaluate the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) events and VTE-related death post-hospital discharge in…
- Conditions
- Heart Failure, Respiratory Insufficiency, Stroke Acute, Infectious Diseases
- Trial name
- MARINER (NCT02111564)
- Testing
- Rivaroxaban, 10 mg, Rivaroxaban, 7.5 mg
- Where
- 593 sites in United States, Argentina and 35 more
- Volunteers
- 12,024 people
- Sponsor
- Janssen Research & Development, LLC
Deep Vein Thrombosis
Reduction to Preventive Doses of Enoxaparin After 3 to 6 Months of Treatment With Blood Thinners for Cancer-associated Blood Clots
Background: Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common cardiovascular disorder after myocardial infarction and stroke.
- Trial name
- STEP-CAT (NCT02752607)
- Where
- 7 sites in Canada
- Volunteers
- 52 people
- Sponsor
- Dr. Vicky Tagalakis
Anemia, Sickle Cell
Therapeutic Anticoagulation Strategy for Acute Chest Syndrome
Acute Chest Syndrome (ACS) is a pulmonary complication of sickle cell disease (SCD) representing the leading cause of death and the second cause of hospitalization among adult patients.
- Conditions
- Anemia, Sickle Cell, Acute Chest Syndrome, Low-Molecular-Weight Heparin
- Trial name
- TASC (NCT02580773)
- Testing
- Prophylactic anticoagulation ( INNOHEP®), Curative anticoagulation ( INNOHEP®)
- Where
- France
- Volunteers
- 198 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Covid19
Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care Units
This is a multi-center, retrospective, study to determine if therapeutic dose anticoagulation (High dose group) improves inpatient mortality in severely ill patients with COVID-19 compared to prophylactic dose anticoagulation…
- Trial name
- NCT04829552
- Where
- United States
- Volunteers
- 704 people
- Sponsor
- Corewell Health East
COVID 19 Associated Coagulopathy
Covid-19 Associated Coagulopathy
This prospective, randomized, open-label, multi-center interventional study is designed to compare the safety and efficacy of two LMWH dosing protocols in patients admitted to the University of Iowa Hospitals with COVID-19 who…
- Trial name
- NCT04360824
- Testing
- Intermediate dose thromboprophylaxis, Standard of Care thromboprophylaxis
- Where
- 2 sites in United States
- Volunteers
- 176 people
- Sponsor
- University of Iowa
Colon Polyp
Prophylactic Clip Application for Colon Polypectomy in Patients With Anticoagulation
There have been very limited evidence about the bleeding complication during colon polypectomy for the patients taking warfarin.
- Trial name
- NCT02120170
- Testing
- Colon polypectomy
- Where
- South Korea
- Volunteers
- 356 people
- Sponsor
- Soonchunhyang University Hospital
Chemotherapeutic Agent Toxicity, Pancreatic Cancer
Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Chemotherapeutic Agent Toxicity, Pancreatic Cancer, Thromboembolism
- Trial name
- PAM07 (NCT00662688)
- Testing
- daltéparine, Chemotherapy at the investigator's discretion
- Where
- 6 sites in France
- Volunteers
- 42 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Liver Cirrhosis, Portal Hypertension
Anticoagulation Therapy After Splenectomy in Cirrhosis Patient
1. Inclusion and Exclusion Criteria Inclusion criteria: Inpatients who received laparotomy or laparoscopic splenectomy according to clinical, B-ultrasound scan, CT or MRI diagnosis of cirrhosis and portal hypertension.
- Conditions
- Liver Cirrhosis, Portal Hypertension, Anticoagulant-induced Bleeding, Thrombosis
- Trial name
- ATASICP (NCT04397289)
- Testing
- Heparin and Rivaroxaban
- Where
- China
- Volunteers
- 70 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Venous Thromboembolism, Cancer
Statins to Prevent Cancer Associated Blood Clots
Patients with cancer are at high risk for life-threatening venous thromboembolism (VTE) yet rarely receive anticoagulant prophylaxis due to bleeding risks.
- Conditions
- Venous Thromboembolism, Cancer, Cardiovascular Events
- Trial name
- STAT-CAT (NCT07303816)
- Testing
- Rosuvastatin
- Where
- 9 sites in United States
- Volunteers
- 4,000 people
- Sponsor
- Brigham and Women's Hospital